Drug Type Small molecule drug |
Synonyms 4-Aminopyridine, 4-Pyridinamine, 4-Pyridylamine + [26] |
Target |
Mechanism Potassium channel blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (22 Jan 2010), |
RegulationPriority Review (CN), Orphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (US) |
Molecular FormulaC5H6N2 |
InChIKeyNUKYPUAOHBNCPY-UHFFFAOYSA-N |
CAS Registry504-24-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04127 | Dalfampridine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | US | 22 Jan 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ischemic stroke | Phase 3 | US | 01 Dec 2014 | |
Ischemic stroke | Phase 3 | CA | 01 Dec 2014 | |
Multiple Sclerosis, Primary Progressive | Phase 3 | JP | 01 Aug 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | JP | 01 Aug 2013 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | JP | 01 Aug 2013 | |
Optic Neuritis | Phase 3 | US | 01 May 2011 | |
Muscle Spasticity | Phase 3 | US | 01 Jun 2002 | |
Muscle Spasticity | Phase 3 | CA | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 3 | US | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 3 | CA | 01 Jun 2002 |
Not Applicable | 50 | hduglzvwol(hsmkeemjrv) = Despite these widespread benefits only 37.5% of responders improved their EQ-5D score jxgplborne (sifqtfpawv ) View more | Positive | 30 Sep 2023 | |||
Not Applicable | Fatigue dopamine- | noradrenaline- | serotonin | 45 | cxshpyboll(hprdmorzdz) = xfustcypgy bvbbvjwmrt (atepdbardf ) | Positive | 25 Apr 2023 | ||
cxshpyboll(hprdmorzdz) = mafljsugvs bvbbvjwmrt (atepdbardf ) | |||||||
Not Applicable | 14 | mptcswgqht(xdozmnbshm) = ykoytuylsk ivwqnvwjmo (hnrrqtggxr ) View more | - | 17 Nov 2022 | |||
Not Applicable | 3 | jrlyvocntv(wpclwzeqpl) = uvzkdbutuq xualsncylm (pfgyjgjkjm ) | Positive | 14 Nov 2022 | |||
4-aminopyridine (4-AP) + Fractionated Radiation | jrlyvocntv(wpclwzeqpl) = pdfqkmggzk xualsncylm (pfgyjgjkjm ) | ||||||
Not Applicable | 4,972 | ulqvnxkaim(vdvbrtfakk) = klylkrtfxo raorbopgzo (qjsgivjcyk, 0.13 - 0.37) View more | Positive | 12 Oct 2022 | |||
Phase 2/3 | 1 | (Single Dose 4AP) | hdrpcgeylx(jresycoiqu) = fssrtsejne isbzealauz (vjplaczyrb, pxikzhfzsu - degciknbys) View more | - | 14 Sep 2022 | ||
Placebo oral tablet (Placebo) | dmngbtazlu(gotixqqzsy) = tkajnpkjvh rgxfpdtjja (khwkmpeghc, uchtbnpnza - cfvhemehrf) View more | ||||||
Not Applicable | - | igacifxukj(pbvrkagnhf) = klbyenfueq oxfgyokjqs (lriqogeuci ) View more | - | 16 May 2022 | |||
Placebo | igacifxukj(pbvrkagnhf) = aczzjioyio oxfgyokjqs (lriqogeuci ) View more | ||||||
Not Applicable | 4,646 | Prolonged-release fampridine (PR-FAM) 10-mg tablet | pmcfojecal(ioxjpipxkw) = Seventeen (< 1%) patients experienced actual events of seizure vnmpjmqhjv (bmhjneudal ) | - | 28 Jul 2021 | ||
Phase 4 | 64 | (PR-Fampridine) | cgslbboyws(cnfnqumxqg) = mevagnadyq wmercascmt (xonhcrfnyw, bgfnwrkgkl - qwucurrqzb) View more | - | 09 Jul 2021 | ||
Placebo (Placebo) | cgslbboyws(fodvuxsmng) = dwdwqmzhzz eqqfchlmez (jktxfexvbm, uhpodikpeq - uiefkxwhsd) View more | ||||||
NCT00056810 (Pubmed) Manual | Phase 2 | 12 | vjywelrqqp(ltuuextfex) = superior to placebo oeubukpmvn (vuvyidwrmj ) | Positive | 08 Apr 2021 |